Blog: Engaging Innovation

Sonia Seth | June 29, 2026

From Innovation to Implementation: What Baby KJ Reveals About the Future of Personalized Therapies

In 2025, an infant known as Baby KJ became one of the first patients to receive a personalized CRISPR-based gene-editing therapy, specifically designed to correct the mutation causing his life-threatening Carbamoyl phosphate synthetase (CPS1) deficiency. This rare metabolic disorder prevents the body from properly clearing ammonia which could lead to rapid toxicity and death without…

Read More

Misha Mehta, PhD - in honor of Neev | June 11, 2026

Advocate Insights | In My Game, Everybody Wins: A Mother’s Case for Federal Investment in Pediatric Brain Tumor Research

My son Neev was four years old when he slid his winning Bingo card across the table to another child. “In my game,” he said, “everybody wins.” He meant it. He lived it. He was the kind of child who made sure every new kid at preschool had someone to sit with at lunch, no teacher had to ask.…

Read More

May 12, 2026

Meeting Recap | Unlocking Next-Generation Therapies

On May 6, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy co-hosted a public meeting, “Unlocking Next-Generation Therapies” to explore opportunities to advance next-generation therapies, including innovative approaches in cell therapy development. The oncology landscape has shifted dramatically over the last 30 years, transitioning from chemotherapy-based treatment toward molecularly and immunologically…

Read More

Grace Collins | May 1, 2026

Stakeholder Connect | Insights from the April 30 Oncologic Drugs Advisory Committee (ODAC) Meeting

What was the committee asked to consider? On April 30, 2026, the U.S. Food and Drug Administration (FDA) convened the Oncologic Drugs Advisory Committee (ODAC) to consider the benefits and risks of two regimens for treatment of cancer.    The morning session focused on the results of the SERENA-6 trial, which was intended to support a new…

Read More

April 14, 2026

Meeting Recap | Application of External Control Arms in Oncology Drug Development

On April 7, Friends of Cancer Research (Friends) hosted a public meeting, “Application of External Control Arms in Oncology Drug Development” to explore opportunities to advance the use of external control arms (ECAs) in oncology drug development. ECAs are constructed from external data sources, such as prior clinical trials or real-world data (RWD), and can provide valuable comparative evidence for evaluating new therapies, particularly when traditional randomized controlled…

Read More

February 17, 2026

Meeting Recap | Modernizing Oncology Endpoints: Pathways for Evidence and Policy

On February 5th, Friends of Cancer Research (Friends) hosted a public meeting, “Modernizing Oncology Endpoints: Pathways for Evidence and Policy” to examine how emerging early endpoints, including circulating tumor DNA (ctDNA) and artificial intelligence (AI)-enabled tumor assessments, may improve trial efficiency and inform regulatory decision-making. Realizing this potential will require convergence around evidentiary standards, scalable validation frameworks, and regulatory pathways that enable innovation to move beyond pilots and into predictable,…

Read More

Elena Levi-D'Ancona, PhD | January 28, 2026

Project Pulse | Modernizing Tumor Assessment: Integrating AI into Oncology Clinical Trials

Friends of Cancer Research (Friends) convened a multidisciplinary working group to examine how to incorporate artificial intelligence (AI) into tumor assessment workflows in oncology clinical trials. The group developed a white paper exploring the potential of emerging AI-enabled tools to enhance tumor assessment, as well as key considerations for the adoption and regulatory approval of AI-enabled imaging endpoints that…

Read More

Elena Levi-D'Ancona, PhD | January 16, 2026

Project Pulse | Evaluating AI Agreement in HER2 Assessment Using Whole-Slide Imaging: Insights from the Digital PATH Project

Biomarkers play a key role in identifying which patients are most likely to benefit from specific therapies, and advances in digital pathology and artificial intelligence (AI) are beginning to reshape how those biomarkers are assessed. Scientists use assays, or tests to assess biomarkers. Outputs from different assays may provide different results, which could impact the…

Read More

Elena Levi-D'Ancona, PhD | January 9, 2026

Data-Driven Insights | The Biomarker Qualification Program: Takeaways and Recommendations

The Prescription Drug User Fee Act (PDUFA) allows the U.S. Food and Drug Administration (FDA) to collect fees from drug sponsors that streamline reviews of new drug applications, promoting timely patient access without compromising safety. When the Act is reauthorized every five years, industry and FDA discuss goals to support and improve the drug review process. With PDUFA negotiations for the 2027 reauthorization now…

Read More

November 21, 2025

Meeting Recap | Advocates Webinar: Annual Meeting 2025

On November 17, Friends of Cancer Research (Friends) convened or an advocates-focused webinar to discuss key themes from the 2025 Annual Meeting and examine how patient experience informs evidence generation, trial design, and regulatory decision-making. We were honored to feature advocate panelists, Kristin McJunkins, Misha Mehta, Susan Rouse, Carol Vallett, and Chris white, who drew…

Read More